Sugi Predict

Sugi Predict / Compounds / SCHEMBL5508642

SCHEMBL5508642

SCHEMBL5508642

O=Cc1cccc(Oc2cccc(Cl)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ HPGD P15428 2/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ GAA P10253 1/20 0.54
▸ TERT O14746 1/20 0.51
▸ SRC P12931 1/20 0.50
▸ CYP1A2 P05177 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ MAOA P21397 7/20 0.47
▸ MAOB P27338 7/20 0.47
▸ ADAMTS5 Q9UNA0 2/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30758642 1.00 MAPT (0.54) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL414827 0.91 TERT (0.61) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL6849018 0.88 SRC (0.60) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL30631693 0.88 SRC (0.60) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL30715071 0.87 HPGD (0.55) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL415226 0.87 HPGD (0.55) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL30758651 0.87 ALDH1A1 (0.47) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL11217503 0.87 HPGD (0.55) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL7761800 0.87 ALDH1A1 (0.47) MAPTKMT2ANPC1RAB9AHPGD
SCHEMBL6852137 0.86 SRC (0.58) MAPTKMT2ANPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250262205-A1 DUAL MAGL AND FAAH INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2025-08-21 — — US disclosed
US-12318383-B2 Dual MAGL and FAAH inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2025-06-03 — — US disclosed
EP-4424683-A2 DUAL MAGL AND FAAH INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2024-09-04 — — EP disclosed
EP-3595665-B1 DUAL MAGL AND FAAH INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER INC (US) 2024-08-28 — — EP disclosed
CN-118271288-A Dual MAGL and FAAH inhibitors 灵北拉荷亚研究中心公司 2024-07-02 — — CN disclosed
CN-117736178-A Dual MAGL and FAAH inhibitors 灵北拉荷亚研究中心公司 2024-03-22 — — CN disclosed
EP-4335848-A2 DUAL MAGL AND FAAH INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2024-03-13 — — EP disclosed
CN-117510468-A Dual MAGL and FAAH inhibitors 灵北拉荷亚研究中心公司 2024-02-06 — — CN disclosed
CN-117466868-A Dual MAGL and FAAH inhibitors 灵北拉荷亚研究中心公司 2024-01-30 — — CN disclosed
US-20210386734-A1 DUAL MAGL AND FAAH INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER, INC. 2021-12-16 — — US disclosed
US-8198303-B2 Methods of use and compositions for the diagnosis and treatment of infectious diseases SEQUELLA, INC. (US) 2012-06-12 — — US disclosed
US-8198303-B2 Methods of use and compositions for the diagnosis and treatment of infectious diseases SEQUELLA, INC. (US) 2012-06-12 — — US disclosed
US-20100273826-A1 METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES SEQUELLA, INC. 2010-10-28 — — US disclosed
US-20100273826-A1 METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES SEQUELLA, INC. 2010-10-28 — — US disclosed
US-7652039-B2 Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis SEQUELLA, INC. (US) 2010-01-26 — — US disclosed
EP-1781271-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 — — EP disclosed
WO-2006019741-A1 ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES JANSSEN PHARMACEUTICA N.V. (BE) 2006-02-23 — — WO disclosed
US-20060014812-A1 Use of estrogen related receptor-modulating aryl ethers JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-19 — — US disclosed
US-5519163-A A-HYDROXYPHOSPHONATE COMPOUNDS MERCK & CO., INC. (US) 1996-05-21 — — US disclosed
EP-0003427-A1 Preparation of m-(p-bromophenoxy)benzaldehyde SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273826-A1 METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES C5, THPO, TERT MAPT 1184/4885KMT2A 2342/4885NPC1 3697/4885
US-20250262205-A1 DUAL MAGL AND FAAH INHIBITORS FAAH, FAAH2, MAG MAPT 812/4885KMT2A 2187/4885NPC1 1227/4885
US-12318383-B2 Dual MAGL and FAAH inhibitors FAAH, FAAH2, MAG MAPT 812/4885KMT2A 2187/4885NPC1 1227/4885
US-20060014812-A1 Use of estrogen related receptor-modulating aryl ethers ESR2, ESRRG, GPER1 MAPT 4442/4885KMT2A 1285/4885NPC1 1413/4885
US-20210386734-A1 DUAL MAGL AND FAAH INHIBITORS FAAH, FAAH2, MAG MAPT 812/4885KMT2A 2187/4885NPC1 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.